Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease

Study Design and Patient Cohort

Phase 1: Participant Recruitment and Characterization (Months 1-6)
Recruit n=60 early-stage Parkinson's Disease patients (Hoehn-Yahr stages 1-2, disease duration <5 years, age 50-75 years) and n=60 age- and sex-matched healthy controls without neurological disease history. Implement rigorous inclusion/exclusion criteria including MRI compatibility, absence of prior stroke or demyelinating disease, and stable medication regimen for ≥3 months. Administer comprehensive clinical assessments including Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Montreal Cognitive Assessment, and olfactory testing. Collect peripheral blood samples and perform genotyping for SNCA, LRRK2, and GBA variants.

...

Study Design and Patient Cohort

Phase 1: Participant Recruitment and Characterization (Months 1-6)
Recruit n=60 early-stage Parkinson's Disease patients (Hoehn-Yahr stages 1-2, disease duration <5 years, age 50-75 years) and n=60 age- and sex-matched healthy controls without neurological disease history. Implement rigorous inclusion/exclusion criteria including MRI compatibility, absence of prior stroke or demyelinating disease, and stable medication regimen for ≥3 months. Administer comprehensive clinical assessments including Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Montreal Cognitive Assessment, and olfactory testing. Collect peripheral blood samples and perform genotyping for SNCA, LRRK2, and GBA variants. Schedule baseline cognitive and motor evaluations with certified raters blinded to group assignment.

Advanced Neuroimaging Protocol

Phase 2A: Multimodal MRI Acquisition (Months 2-8)
Perform 3T MRI imaging using standardized sequences at a single imaging center with quality assurance protocols. Acquire myelin water imaging (MWI) using 32-echo T2 relaxation sequences with voxel resolution 3×3×4mm³, enabling quantification of myelin water fraction (MWF) across white matter regions of interest (ROI): corpus callosum, anterior/posterior thalamic radiations, superior longitudinal fasciculus, and corticospinal tracts. Implement magnetization transfer ratio (MTR) imaging with on-resonance and off-resonance saturation pulses at 1.2 kHz offset, acquiring high-resolution 3D FLASH sequences. Perform diffusion tensor imaging (DTI) with b-values 0 and 1000 s/mm² across 64 gradient directions, calculating fractional anisotropy (FA), mean diffusivity (MD), and axial/radial diffusivity. Conduct quantitative susceptibility mapping (QSM) to assess iron accumulation in substantia nigra and globus pallidus. Utilize tract-based spatial statistics (TBSS) for white matter skeleton analysis with nonlinear registration to FMRIB58_FA standard space. Implement longitudinal follow-up imaging at 12 and 24 months to assess progressive myelin deterioration rates.

Cerebrospinal Fluid Biomarker Analysis

Phase 2B: Lumbar Puncture and Biomarker Quantification (Months 3-9)
Perform lumbar puncture at L3-L4 or L4-L5 interspace under sterile conditions, collecting 10-15mL CSF in polypropylene tubes. Centrifuge samples at 300×g for 10 minutes at 4°C within 30 minutes of collection and store at -80°C in aliquots for batch analysis. Quantify oligodendrocyte-derived biomarkers using ultrasensitive immunoassays: (1) CNP (2',3'-cyclic nucleotide 3'-phosphodiesterase) via electrochemiluminescence immunoassay with lower detection limit 0.05pg/mL; (2) MOG (myelin oligodendrocyte glycoprotein) and MBP (myelin basic protein) via ELISA with intra-assay coefficient of variation <8%; (3) phosphorylated tau (p-tau181) and alpha-synuclein oligomers via digital ELISA for neuroinflammatory correlation. Measure lipid-metabolic markers including sulfatide, ceramide, and ganglioside GM1 using liquid chromatography-tandem mass spectrometry (LC-MS/MS) with isotope-labeled internal standards. Correlate CSF biomarkers with imaging metrics using Pearson correlation analysis stratified by disease stage.

Tissue Acquisition and Single-Cell Analysis

Phase 3A: Postmortem Brain and Biopsy Sampling (Months 4-18)
For deceased PD patients enrolled in brain donation program, coordinate rapid autopsy within 4-12 hours post-mortem. Dissect 2-3mg tissue samples from defined white matter regions (genu of corpus callosum, anterior thalamic radiation) and dopamine-rich regions (substantia nigra pars compacta, ventral tegmental area). Prepare tissue sections for transmission electron microscopy (TEM) with 70-90nm ultramicrotomy sections. Process tissue for single-nucleus RNA-sequencing (snRNA-seq) using ATAC-seq compatible protocols on isolated nuclei with fluorescence-activated nuclei sorting (FANS) enrichment for oligodendrocyte lineage cells (SOX10+, CNP+, OLIG2+). Generate transcriptomic libraries with 10x Genomics Chromium platform targeting >50,000 nuclei per sample, achieving >20,000 UMI recovery per nucleus. Perform quality control with minimum 200 genes detected per nucleus, maintaining <10% mitochondrial gene expression.

Immunohistochemistry and Ultrastructural Analysis

Phase 3B: Morphological and Molecular Characterization (Months 5-20)
Conduct multiplex immunofluorescence on 5-10μm cryosections using antibodies against: OLIG2 (oligodendrocyte lineage), CC1/APC (mature oligodendrocyte), CNP (myelin), MBP (myelin basic protein), p-α-synuclein (Ser129 phosphorylation), and DAPI nuclear counterstain. Acquire images on confocal microscope with 63x/1.4NA oil immersion objective at 512×512 pixel resolution with z-stacks (0.3μm spacing). Perform stereological quantification of oligodendrocyte density, soma area, and process branching complexity in at least 10 ROIs per sample (minimum 500μm² per ROI). Conduct electron microscopy ultrastructural analysis quantifying myelin lamella periodicity, internodal segment length, and g-ratio (axon diameter/fiber diameter) in minimum n=100 axons per sample. Assess oligodendrocyte organelle ultrastructure including mitochondrial cristae organization, rough endoplasmic reticulum expansion, and autophagosome abundance as markers of cellular stress.

Show more

Show more

Prerequisites

Blocks